Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 17, 2005 Charly Travers	BioMarin Bounces Back After a stumble, one biotech firm is returning to the market's good graces. BioMarin stock has shot up 30% in the past two months and is near its 52-week high.
The Motley Fool May 2, 2007 Brian Lawler	BioMarin Moves Ahead The drug developer released first-quarter financial results. Even though BioMarin is not yet profitable, its management team has proven capable in all areas of drug development, from the clinical stage to commercialization. Investors, take note.
The Motley Fool February 27, 2007 Brian Lawler	Mostly Good From BioMarin Drugmaker BioMarin updates investors on its drug pipeline and quarterly financial results.
The Motley Fool April 1, 2008 Brian Lawler	BioMarin Drug Heads Overseas One of the pharmaceutical's enzyme replacement therapy drugs gets approved in Japan.
The Motley Fool August 9, 2007 Brian Lawler	BioMarin Gets Busy BioMarin Pharmaceutical has a busy remainder of 2007 ahead of it, including regulatory decisions, six clinical trials, and the potential for new products to enter the pipeline.
The Motley Fool April 30, 2008 Brian Lawler	BioMarin's Bodacious Earnings BioMarin raises revenue guidance for all of its marketed drugs, thanks to strong sales so far in 2008.
The Motley Fool February 28, 2011 Brian Orelli	Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on.
The Motley Fool March 1, 2005 Charly Travers	From Rags to Riches One biotech's fate reveals the formula for spotting turnaround investments. BioMarin has yet to turn the corner, but that time is quickly approaching.
The Motley Fool July 31, 2009 Brian Orelli	The Little Orphan That Could After a rough start to the year, Rule Breakers pick BioMarin Pharmaceutical is back on track.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool October 8, 2007 Charly Travers	Scanning 4 Biotechs There are major events set for the following biotech companies during this quarter. Investors, take note: BioMarin Pharmaceutical... Exelixis... Neurocrine Biosciences... Pain Therapeutics...
The Motley Fool August 6, 2008 Brian Lawler	BioMarin's New Drugs Mostly Hit Their Targets Near-term volatility in a drugmaker's shares can make for long-term opportunities. Such is the current case with BioMarin Pharmaceutical.
The Motley Fool May 31, 2011 David Williamson	Roundtable: The World's Best Biotechs Motley Fool analysts choose these as their favorite biotech stocks: Aeterna Zentaris... Seattle Genetics... BioMarin Pharmaceutical... Amarin...
The Motley Fool October 29, 2009 Brian Orelli	Small and Volatile, but Not for Long BioMarin is growing.
The Motley Fool June 3, 2004 Charly Travers	Small Drug Market, Big Hopes BioMarin is going to file for approval in the U.S. and Europe in the fourth quarter of this year after its succesful phase 3 trial of Aryplase. If the drug is approved, it would likely be on the market toward the end of 2005.
The Motley Fool October 9, 2006 Brian Lawler	The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field.
The Motley Fool May 25, 2007 Brian Lawler	BioMarin Waits for Another Drug BioMarin files a marketing application for its lead compound in development. Investors, take note.
The Motley Fool August 9, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool September 2, 2010 Brian Orelli	Pfizer Takes an Orphan Into the Fold Pfizer is likely pursuing FoldRx's pipeline and expertise in rare diseases.
The Motley Fool September 8, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool February 19, 2009 Brian Orelli	BioMarin Is Off Track Shares of BioMarin Pharmaceutical, a darling of the drug world whose shares more than doubled in 2007, come crashing down because the growth of years past seems to be waning.
The Motley Fool May 3, 2007	BioMarin's Big Moves: Fool by Numbers The pharmaceutical released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
Chemistry World March 2011	Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations
The Motley Fool February 18, 2005 John Bluis	Genzyme's Acquisitions Pay Off With some of this biotech's major decisions coming to fruition, shareholders can have more confidence that management can deliver on its promises.
The Motley Fool December 29, 2011 Brian Orelli	Too Early for a New Biotech Orphan? Alexion Pharmaceuticals is profitable with a drug on the market. The next logical step in the progression of a biotech is to buy another company to stock the pipeline.
Chemistry World November 2010	Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream?
The Motley Fool October 30, 2009 Brian Orelli	Earnings? Yawn. Trial Data? Moving! For Human Genome Sciences investors, the anticipation is frightening.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
The Motley Fool March 27, 2009 Brian Orelli	Trading Up With the $95 From Genentech Genentech is gone; here's what you should replace it with.
The Motley Fool April 16, 2004 Charly Travers	Genzyme's Minor Disappointment The latest sales figures for Genzyme's newest drug, Aldurazyme, show that a potential growth-driving drug may be stalling out.
The Motley Fool November 8, 2007 Charly Travers	BioMarin Tips Its Hand BioMarin Pharmaceutical awaits an FDA decision on its drug Kuvan for the treatment of phenylketonuria. The company's recent conference call implies approval is imminent.
The Motley Fool May 10, 2011 Brian Orelli	Uncontrolled Crying Over AVANIR's Prescription Data? It's been a slow start, but don't write off this company's pseudobulbar drug just yet.
The Motley Fool June 12, 2009 Brian Orelli	Where Good Drugs Go to Die Human Genome Sciences has the potential to pop if Benlysta's phase 3 trials are a success, but tread lightly, history is not on their side.
The Motley Fool February 26, 2007	BioMarin's Big Quarter: Fool by Numbers The pharmaceutical released fourth-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool November 12, 2010 Brian Orelli	Benlysta: Not Perfect, but Good Enough Human Genome should get past the FDA advisory panel next week.
The Motley Fool June 16, 2009 Brian Orelli	Going Viral, but Not in a Good Way Genzyme's manufacturing problems with viruses underscore the complexity of manufacturing biologic drugs compared to small molecule drugs.
The Motley Fool August 26, 2010 Travers & Jayson	Will BioMarin Pharmaceutical Burn You? Is BioMarin Pharmaceutical on strong financial footing?
The Motley Fool December 13, 2010 Brian Orelli	Yep, We Still Want to Lowball You sanofi-aventis still wants investors shares in Genzyme, but it's not willing to step up the price.
The Motley Fool October 27, 2009 Brian Orelli	Small Market, Small Acquisition, Still a Good Move BioMarin does everything small.
The Motley Fool December 18, 2008 Brian Orelli	Pfizer Needs Bigger Deals Buy something significant already!
The Motley Fool November 14, 2007 Brian Lawler	Is the FDA Still Approving New Drugs? Lately the FDA seems more reluctant to approve new drugs than it once was. Let's take a look at the actual numbers from the past eight years.
The Motley Fool January 7, 2009 Brian Orelli	A Free Call Option on a Drug Orphan-drug specialist BioMarin announces that it has licensed Riquent, La Jolla Pharmaceutical's phase 3 lupus nephritis treatment.
The Motley Fool January 21, 2010 Brian Orelli	The Noble Gesture That Wasn't There may be a motive behind Glaxo helping to develop malaria treatments.
The Motley Fool February 12, 2009 Brian Orelli	Cruising, but Ready to Take Off Genzyme's in wait-and-see mode.
The Motley Fool September 24, 2004 Charly Travers	BioMarin Blew It Big-Time On Tuesday the company revised its financial guidance for the year with anticipated revenues from recently acquired drug Orapred coming in at a whopping total of zero.
Pharmaceutical Executive December 1, 2011 Ben Comer	Pharm Exec's 2012 Pipeline Report It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle?
The Motley Fool August 28, 2009 Brian Orelli	Is There Life After a 714% Return? It doesn't get any less risky for Immunomedics.
The Motley Fool December 16, 2011 Brian Orelli	Biotech Royalties, Almost as Good as Cash They're flexible, and all royalties have value.
The Motley Fool February 24, 2009 Brian Orelli	Back to the Red, but Not for Long After a few quarters in the black, Onyx Pharmaceuticals slips back into the red, reporting a loss of $30 million for the fourth quarter.